AI Insight
Researchers developed TransMap, a computational framework that maps how genetic variants distally regulate gene expression and biological programs in the aging human brain. Applied to brain tissue from 476 donors, the method identified nearly 50,000 trans-regulatory events and revealed that genetic variants affecting neuronal genes preferentially trigger coordinated responses in glial cells. The analysis connected 115 Alzheimer's disease risk loci to specific regulatory mechanisms, including a link between KNOP1 and microglial gene programs.
Why it matters
This framework provides a cell-type-specific atlas of how genetic variation influences brain function and disease risk through distant regulatory effects. The findings could help identify new therapeutic targets for Alzheimer's disease and other brain disorders by clarifying the molecular mechanisms linking genetic risk variants to disease.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Mapping genetic effects on distal genes and regulatory programs is essential for understanding how genetic variation influences complex diseases; yet trans-QTL discovery remains limited by weak effect sizes, extensive multiple testing and poor reproducibility. Here, we introduce TransMap, a generalizable computational framework that combines multi-scale trans-QTL mapping with multi-phenotype genetic colocalization to improve the discovery and interpretation of distal regulatory variants. Beyond individual trans-eGenes, TransMap constructs local co-regulatory program phenotypes that account for background expression variation to improve the detection of weak, coordinated distal genetic effects. Across a broad range of simulation settings, TransMap achieved 9.2-36.7% higher trans-QTL discovery power than existing methods while maintaining well-controlled type I error rates. We applied TransMap to bulk and single-nucleus transcriptomic profiles from the aging human brain in the ADSP Functional Genomics Consortium (FunGen-AD), further integrating proteomic, glycoproteomic and metabolomic biomarker measurements (average N=476 donors). Genome-wide fine-mapping of TransMap single-gene and program-level QTL yielded variant annotations with 2.75-2.88x heritability enrichment across 57 complex diseases and traits (average N=307K), with complementary heritability information captured across regulatory scales. Multi-phenotype colocalization identified 49,532 trans-regulatory events supported by shared genetic signals with cis-eQTL or biomarker-QTL, including 1,825 candidate cis-trans-biomarker regulatory configurations. TransMap further revealed an asymmetric cross-cell-type regulatory architecture in which neuronal cis-regulatory signals preferentially associate with coordinated glial trans-regulatory responses, supported by co-culture experiments and spatial transcriptomics. Alzheimer’s disease (AD) GWAS-prioritized colocalization identified trans-regulatory associations in 115 AD-associated loci, including a KNOP1 cis-eQTL associated in trans with a microglial regulatory program containing MS4A4E, with additional support from statistical mediation analysis. TransMap provides a multi-scale, cell-type-resolved atlas of trans-regulatory variation and a generalizable framework for elucidating the regulatory architecture of complex diseases.
Source: A multi-scale cell-type resolved map of trans-regulatory architecture in the aging human brain